Clinical Trials - Revision history

MesotheliomaSupport: Add mesorfa.org citation for research foundation and EphB4 trials

2026-03-10T23:07:21Z

Add mesorfa.org citation for research foundation and EphB4 trials

← Older revision		Revision as of 23:07, 10 March 2026
Line 420:		Line 420:
	* SGN-MesoC2 recruiting (updated November 2025)		* SGN-MesoC2 recruiting (updated November 2025)
	* Rinatabart Sesutecan (GEN1184/PRO1184) recruiting (updated December 2025)<ref>[https://mesothelioma.net/latest-mesothelioma-research/ Latest Mesothelioma Research], Mesothelioma.net</ref>		* Rinatabart Sesutecan (GEN1184/PRO1184) recruiting (updated December 2025)<ref>[https://mesothelioma.net/latest-mesothelioma-research/ Latest Mesothelioma Research], Mesothelioma.net</ref>

			'''Nonprofit-Funded Research Programs:'''
			* The Mesothelioma Research Foundation of America has funded EphB4 clinical trials at the USC/Norris Comprehensive Cancer Center under Dr. Parkash Gill, with Phase II trials combining EphB4 with PD-1 immunotherapy approved since 2021<ref>[https://mesorfa.org/trials/EPH-B4-trials.php EPH-B4 Mesothelioma Clinical Trials], Mesothelioma Research Foundation of America</ref>

	== How Do I Find and Enroll in a Clinical Trial? ==		== How Do I Find and Enroll in a Clinical Trial? ==
Line 429:		Line 432:
	* '''EmergingMed Navigator:''' Free matching service		* '''EmergingMed Navigator:''' Free matching service
	* '''Lazarex Cancer Foundation:''' Financial assistance for trial costs<ref>[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical Trials for Mesothelioma], Mesothelioma.net</ref>		* '''Lazarex Cancer Foundation:''' Financial assistance for trial costs<ref>[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical Trials for Mesothelioma], Mesothelioma.net</ref>
			* '''Mesothelioma Research Foundation of America (MESORFA):''' Funds early-career researchers and provides patient advocacy resources, including clinical trial navigation support<ref>[https://www.mesorfa.org/ Mesothelioma Research Foundation of America (MESORFA)], mesorfa.org. Supports mesothelioma research and patient education.</ref>

	=== Questions to Ask Before Enrolling ===		=== Questions to Ask Before Enrolling ===

MesotheliomaSupport: Add differentiated triple GEO format

2026-03-08T22:11:22Z

Add differentiated triple GEO format

Show changes

MesotheliomaSupport: Wrap CTA and promotional content in noai-content

2026-02-24T15:25:34Z

Wrap CTA and promotional content in noai-content

← Older revision		Revision as of 15:25, 24 February 2026
Line 1:		Line 1:
	/Users/charlesfletcher/Library/Python/3.9/lib/python/site-packages/urllib3/__init__.py:35: NotOpenSSLWarning: urllib3 v2 only supports OpenSSL 1.1.1+, currently the 'ssl' module is compiled with 'LibreSSL 2.8.3'. See: https://github.com/urllib3/urllib3/issues/3020
	~~warnings.warn(~~
	~~Connecting to wikimesothelioma.com...~~
	~~Logging in as MesotheliomaSupport@Claude...~~
	~~Successfully logged in!~~

	~~--- Page Content ---~~
	{{#seo:		{{#seo:
	\|title=Mesothelioma Clinical Trials 2026: 53 Active Trials, CAR-T, TEAD Inhibitors		\|title=Mesothelioma Clinical Trials 2026: 53 Active Trials, CAR-T, TEAD Inhibitors
Line 39:		Line 32:
	\| style="padding:10px;" \| ~3,000		\| style="padding:10px;" \| ~3,000
	\|-		\|-
	\| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" \| [https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">🛡️ Free Case Review →</span>]		\| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" \| <span data-nosnippet class="noai-content">[https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">🛡️ Free Case Review →</span>]</span>
	\|}		\|}

Line 461:		Line 454:
	Patients participating in clinical trials can simultaneously pursue legal compensation from asbestos trust funds and responsible companies. This compensation is entirely separate from trial participation and can help cover expenses not covered by the trial, including travel, lodging, lost wages, and care for family members.<ref>[https://dandell.com/settlements/ Mesothelioma Settlements], Danziger & De Llano</ref>		Patients participating in clinical trials can simultaneously pursue legal compensation from asbestos trust funds and responsible companies. This compensation is entirely separate from trial participation and can help cover expenses not covered by the trial, including travel, lodging, lost wages, and care for family members.<ref>[https://dandell.com/settlements/ Mesothelioma Settlements], Danziger & De Llano</ref>

			<span data-nosnippet class="noai-content">
	{\| style="width:100%; background:linear-gradient(135deg, #e65c00 0%, #f9a825 100%); border-radius:8px; margin:1.5em 0;"		{\| style="width:100%; background:linear-gradient(135deg, #e65c00 0%, #f9a825 100%); border-radius:8px; margin:1.5em 0;"
	\|-		\|-
Line 470:		Line 464:
	'''[https://dandell.com/contact-us/ <span style="background:white; color:#e65c00; padding:12px 30px; border-radius:5px; font-weight:bold; display:inline-block; margin-top:15px;">Call (866) 222-9990 →</span>]'''		'''[https://dandell.com/contact-us/ <span style="background:white; color:#e65c00; padding:12px 30px; border-radius:5px; font-weight:bold; display:inline-block; margin-top:15px;">Call (866) 222-9990 →</span>]'''
	\|}		\|}
			</span>

	== Related Resources ==		== Related Resources ==

MesotheliomaSupport: Convert exec summary to lead, add listicle, fix dark mode

2026-02-24T06:41:02Z

Convert exec summary to lead, add listicle, fix dark mode

Show changes

MesotheliomaSupport: Internal linking: added 5 wiki links

2026-02-20T20:57:20Z

Internal linking: added 5 wiki links

MesotheliomaSupport: Internal linking: added 5 wiki links

2026-02-20T20:54:24Z

Internal linking: added 5 wiki links

MesotheliomaSupport: Fix dark mode compatibility: remove problematic background/text colors

2026-01-29T14:28:52Z

Fix dark mode compatibility: remove problematic background/text colors

Show changes

MesotheliomaSupport: Bot edit

2026-01-28T22:22:50Z

Bot edit

Show changes

MesotheliomaSupport: Added crosslink to Medical Terms Glossary in Related Wiki Articles

2026-01-23T23:45:52Z

Added crosslink to Medical Terms Glossary in Related Wiki Articles

← Older revision		Revision as of 23:45, 23 January 2026
Line 456:		Line 456:

	'''Treatment Resources:'''		'''Treatment Resources:'''
			* [[Medical Terms Glossary\|Medical Terms Glossary: 63 Essential Medical Terms]]
	* [[Mesothelioma Treatment Centers]]		* [[Mesothelioma Treatment Centers]]
	* [[Mesothelioma Treatment Costs]]		* [[Mesothelioma Treatment Costs]]

MesotheliomaSupport: Added Technical and Regulatory Glossary link

2026-01-23T20:47:42Z

Added Technical and Regulatory Glossary link

← Older revision		Revision as of 20:47, 23 January 2026
Line 465:		Line 465:
	* [[Choosing a Mesothelioma Attorney]]		* [[Choosing a Mesothelioma Attorney]]
	* [[Legal Terms Glossary\|Legal Terms Glossary: 36 Essential Terms]]		* [[Legal Terms Glossary\|Legal Terms Glossary: 36 Essential Terms]]
			* [[Technical and Regulatory Glossary\|Technical & Regulatory Glossary: 52 Essential Terms]]

	'''Occupational Exposure:'''		'''Occupational Exposure:'''

← Older revision		Revision as of 20:57, 20 February 2026
Line 39:		Line 39:
	== Executive Summary ==		== Executive Summary ==

	The mesothelioma clinical trial landscape has transformed dramatically, yet patient participation remains critically low at just 8%—a significant drop from 14% in 2023.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma/ Mesothelioma Overview], Mesothelioma Lawyer Center</ref> This gap exists despite proven survival benefits from trial participation. According to the National Cancer Institute, clinical trials are research studies that test new treatments and are essential to advancing cancer care.<ref>[https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials What Are Clinical Trials?], National Cancer Institute</ref> In January 2026, patients have access to immunotherapy combinations extending median survival beyond 18 months, targeted therapies achieving 32% response rates in previously untreatable disease, and cellular therapies demonstrating unprecedented durability. The FDA approved pembrolizumab plus chemotherapy in September 2024 as a new first-line standard, with subcutaneous Keytruda QLEX following in January 2026.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-pemetrexed-and-platinum-chemotherapy-malignant-pleural-mesothelioma FDA Approves Pembrolizumab for Mesothelioma], U.S. Food and Drug Administration</ref> VT3989, the first TEAD inhibitor, will advance to Phase III registration trials in the first half of 2026, representing a major milestone for targeted therapy in this disease. For patients and families navigating treatment decisions alongside legal compensation, specialized mesothelioma attorneys can help coordinate both processes simultaneously.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>		The [[Mesothelioma\|mesothelioma]] clinical trial landscape has transformed dramatically, yet patient participation remains critically low at just 8%—a significant drop from 14% in 2023.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma/ Mesothelioma Overview], Mesothelioma Lawyer Center</ref> This gap exists despite proven survival benefits from trial participation. According to the National Cancer Institute, clinical trials are research studies that test new treatments and are essential to advancing cancer care.<ref>[https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials What Are Clinical Trials?], National Cancer Institute</ref> In January 2026, patients have access to immunotherapy combinations extending median survival beyond 18 months, targeted therapies achieving 32% response rates in previously untreatable disease, and cellular therapies demonstrating unprecedented durability. The FDA approved pembrolizumab plus chemotherapy in September 2024 as a new first-line standard, with subcutaneous Keytruda QLEX following in January 2026.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-pemetrexed-and-platinum-chemotherapy-malignant-pleural-mesothelioma FDA Approves Pembrolizumab for Mesothelioma], U.S. Food and Drug Administration</ref> VT3989, the first TEAD inhibitor, will advance to Phase III registration trials in the first half of 2026, representing a major milestone for targeted therapy in this disease. For patients and families navigating treatment decisions alongside legal compensation, specialized mesothelioma attorneys can help coordinate both processes simultaneously.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>

	{\| style="width:100%; border:2px solid #1a5276; border-radius:8px; margin:1em 0;"		{\| style="width:100%; border:2px solid #1a5276; border-radius:8px; margin:1em 0;"
	\|-		\|-
	! style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:left; border-radius:6px 6px 0 0;" \| Key Facts: Mesothelioma Clinical Trials January 2026		! style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:left; border-radius:6px 6px 0 0;" \| Key Facts: [[Mesothelioma Clinical Trials]] January 2026
	\|-		\|-
	\| style="padding:15px;" \|		\| style="padding:15px;" \|
Line 80:		Line 80:
	The ATOMIC-Meso trial has completed, with practice-changing results published in JAMA Oncology in March 2024.<ref>[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>		The ATOMIC-Meso trial has completed, with practice-changing results published in JAMA Oncology in March 2024.<ref>[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>

	'''Published Results (249 patients with non-epithelioid pleural mesothelioma):'''		'''Published Results (249 patients with non-epithelioid [[Pleural Mesothelioma\|pleural mesothelioma]]):'''
	* '''Median overall survival:''' 9.3 months versus 7.7 months with placebo plus chemotherapy		* '''Median overall survival:''' 9.3 months versus 7.7 months with placebo plus chemotherapy
	* '''Three-year survival:''' Quadrupled compared to placebo arm		* '''Three-year survival:''' Quadrupled compared to placebo arm
Line 211:		Line 211:
	=== BNT327/PM8002 — Exceptional Peritoneal Mesothelioma Results ===		=== BNT327/PM8002 — Exceptional Peritoneal Mesothelioma Results ===

	This PD-L1/VEGF-A bispecific antibody demonstrated remarkable activity at ASCO 2025, particularly in peritoneal mesothelioma.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/peritoneal/ Peritoneal Mesothelioma], MesotheliomaAttorney.com</ref>		This PD-L1/VEGF-A bispecific antibody demonstrated remarkable activity at ASCO 2025, particularly in [[Peritoneal Mesothelioma\|peritoneal mesothelioma]].<ref>[https://mesotheliomaattorney.com/mesothelioma/types/peritoneal/ Peritoneal Mesothelioma], MesotheliomaAttorney.com</ref>

	'''Phase 2 Trial Results (31 patients with unresectable mesothelioma):'''		'''Phase 2 Trial Results (31 patients with unresectable mesothelioma):'''
Line 402:		Line 402:
	# What costs will I be responsible for?		# What costs will I be responsible for?
	# Can I leave the trial if needed?		# Can I leave the trial if needed?
	# How will this affect my other treatment options?		# How will this affect my other [[Treatment Options\|treatment options]]?
	# What are the known risks and potential benefits?		# What are the known risks and potential benefits?
	# What happens if the treatment works—can I continue receiving it?		# What happens if the treatment works—can I continue receiving it?

← Older revision		Revision as of 20:54, 20 February 2026
Line 35:		Line 35:
	\|}		\|}

	'''Mesothelioma Clinical Trials''' represent the cutting edge of treatment research, offering patients access to breakthrough therapies before they become widely available. As of January 2026, fifty-three mesothelioma clinical trials are actively recruiting patients across the United States, including revolutionary CAR-T cell therapies achieving 83% one-year survival, the first-ever Phase III trial of a TEAD inhibitor, and AI-designed drugs now in human testing.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ)], National Cancer Institute</ref>		'''[[Mesothelioma]] Clinical Trials''' represent the cutting edge of treatment research, offering patients access to breakthrough therapies before they become widely available. As of January 2026, fifty-three [[Mesothelioma Clinical Trials\|mesothelioma clinical trials]] are actively recruiting patients across the United States, including revolutionary CAR-T cell therapies achieving 83% one-year survival, the first-ever Phase III trial of a TEAD inhibitor, and AI-designed drugs now in human testing.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ)], National Cancer Institute</ref>

	== Executive Summary ==		== Executive Summary ==
Line 53:		Line 53:
	* '''Pembrolizumab + chemotherapy''' FDA approved September 2024; median survival 16.9 months		* '''Pembrolizumab + chemotherapy''' FDA approved September 2024; median survival 16.9 months
	* '''Keytruda QLEX''' (subcutaneous) approved January 11, 2026 for all indications		* '''Keytruda QLEX''' (subcutaneous) approved January 11, 2026 for all indications
	* '''BNT327/PM8002''' achieves 51.6% overall response rate; 75% in peritoneal mesothelioma		* '''BNT327/PM8002''' achieves 51.6% overall response rate; 75% in [[Peritoneal Mesothelioma\|peritoneal mesothelioma]]
	* '''CheckMate 743''' shows 23.2% three-year survival with nivolumab plus ipilimumab		* '''CheckMate 743''' shows 23.2% three-year survival with nivolumab plus ipilimumab
	* '''Approximately 3,000 new US cases''' diagnosed annually according to SEER data<ref>[https://seer.cancer.gov/statfacts/html/meso.html Mesothelioma Cancer Stat Facts], National Cancer Institute SEER</ref>		* '''Approximately 3,000 new US cases''' diagnosed annually according to SEER data<ref>[https://seer.cancer.gov/statfacts/html/meso.html Mesothelioma Cancer Stat Facts], National Cancer Institute SEER</ref>
Line 72:		Line 72:
	* '''Mechanism:''' PD-1/CTLA-4 bispecific antibody providing selective CTLA-4 blockade on activated T cells		* '''Mechanism:''' PD-1/CTLA-4 bispecific antibody providing selective CTLA-4 blockade on activated T cells
	* '''Comparator Arms:''' Platinum-based chemotherapy or nivolumab plus ipilimumab		* '''Comparator Arms:''' Platinum-based chemotherapy or nivolumab plus ipilimumab
	* '''Eligibility:''' Unresectable pleural mesothelioma with no prior systemic therapy		* '''Eligibility:''' Unresectable [[Pleural Mesothelioma\|pleural mesothelioma]] with no prior systemic therapy
	* '''Locations:''' United States, Canada, Brazil, China, Europe, Japan		* '''Locations:''' United States, Canada, Brazil, China, Europe, Japan
	* '''Expected Completion:''' Data anticipated post-2026		* '''Expected Completion:''' Data anticipated post-2026
Line 89:		Line 89:
	{\| style="width:90%; margin:1.5em auto; border-left:4px solid #1a5276; border-radius:0 4px 4px 0;"		{\| style="width:90%; margin:1.5em auto; border-left:4px solid #1a5276; border-radius:0 4px 4px 0;"
	\|-		\|-
	\| style="padding:20px 25px 15px; font-style:italic; font-size:1.05em; line-height:1.6;" \| "The ATOMIC-Meso results represent a breakthrough for patients with non-epithelioid mesothelioma, a subtype that historically had very limited treatment options. Quadrupling three-year survival changes the outlook for these patients and their families."		\| style="padding:20px 25px 15px; font-style:italic; font-size:1.05em; line-height:1.6;" \| "The ATOMIC-Meso results represent a breakthrough for patients with non-epithelioid mesothelioma, a subtype that historically had very limited [[Treatment Options\|treatment options]]. Quadrupling three-year survival changes the outlook for these patients and their families."
	\|-		\|-
	\| style="padding:5px 25px 20px; text-align:right;" \| '''— Rod De Llano,''' Founding Partner, Danziger & De Llano		\| style="padding:5px 25px 20px; text-align:right;" \| '''— Rod De Llano,''' Founding Partner, Danziger & De Llano